Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer

Acta Oncologica

Volumn 47, Issue 3, 2008, Pages 442-450

  Tao, Yungan ^a,b   Lefkopoulos, Dimitri ^a   Ibrahima, Diallo ^a,c,d   Bridier, Andre ^a   Polizzi, Maria Del Pilar ^a   Wibault, Pierre ^a   De Crevoisier, Renaud ^a   Arriagada, Rodrigo ^a,c,d,e   Bourhis, Jean ^a,c,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b FUDAN UNIVERSITY   (China)

^c INSERM   (France)

^d University of Paris South   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLADDER; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; FEMUR HEAD; HISTOGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MALE; PATIENT SELECTION; PELVIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION FIELD; RECTUM; SEMINAL VESICLE;

ADENOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMUR HEAD; HUMANS; MALE; PELVIS; PROSTATE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; SEMINAL VESICLES; URINARY BLADDER;

EID: 40949141043     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701666055     Document Type: Article

References (28)

1. Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, Horwich A. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 2005;41:908-21.
2. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
3. Lebesque JV, van Putten WLJ, Heemsbergen WD. Radiation dose-response in prostate cancer: Results of a multicenter randomized phase III trial comparing 68Gy with 78Gy [Abstract]. Eur J Cancer 2005;(Suppl 3):3 PS3.
4. Tucker SL, Cheung R, Dong L, Liu HH, Thames HD, Huang EH, et al. Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:353-65.
5. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrun S, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000;47:103-13.
6. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6.
7. Hong TS, Ritter MA, Tome WA, Harari PM. Intensity-modulated radiation therapy: Emerging cancer treatment technology. Br J Cancer 2005;92:1819-24.
8. Bucci MK, Bevan A, Roach M, 3rd. Advances in radiation therapy: Conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005;55:117-34.
9. Hall EJ, Wuu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8.
10. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406.
11. Sigurdson AJ, Jones IM. Second cancers after radiotherapy: Any evidence for radiation-induced genomic instability? Oncogene 2003;22:7018-27.
12. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-94.
13. Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165-71.
14. Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: A population-based study. Gastroenterology 2005;128:819-24.
15. Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer 2006;107:991-8.
16. Diallo I, Lamon A, Shamsaldin A, Grimaud E, de Vathaire F, Chavaudra J. Estimation of the radiation dose delivered to any point outside the target volume per patient treated with external beam radiotherapy. Radiother Oncol 1996;38:269-71.
17. Shamsaldin A, Grimaud E, Hardiman C, Diallo I, de-Vathaire F, Chavaudra J. Dose distribution throughout the body from radiotherapy for Hodgkin's disease in childhood. Radiother Oncol 1998;49:85-90.
18. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000;55:241-9.
19. Marchal C, Lapeyre M, Beckendorf V, Aletti P, Hasle E, Dubois JB, et al. Preliminary results of the assessment of intensity modulated radiotherapy (IMRT) for prostatic and head and neck tumors (STIC 2001). Cancer Radiother 2004;8(Suppl)(1):S121-7.
20. Chauvet I, Gaboriaud G, Pontvert D, Zefkili S, Giraud P, Rosenwald JC, et al. Constraints and dosage for prostate cancer patients treated with conformal radiotherapy and intensity modulated radiation therapy. Cancer Radiother 2004;8:337-51.
21. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, et al. Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005;62:1204-16.
22. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005;62:1195-203.
23. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-92.
24. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-75.
25. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65.
26. Prevost JB, Bossi A, Sciot R, Debiec-Rychter M. Post-irradiation sarcoma after external beam radiation therapy for localized adenocarcinoma of the prostate. Tumori 2004;90:618-21.
27. Rubino C, de Vathaire F, Shamsaldin A, Labbe M, Le MG. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003;89:840-6.
28. Rubino C, Shamsaldin A, Le MG, Labbe M, Guinebretiere JM, Chavaudra J, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005;89:277-88.